Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing

An antibody directed against the O-antigen of Pseudomonas aeruginosa LPS can block complement-mediated bacterial killing and contributes to the severity of respiratory infection.

[1]  H. Reynolds,et al.  Immunoglobulin-G Subclasses in Cystic Fibrosis , 2015 .

[2]  Jacky Flipse,et al.  Molecular Mechanisms Involved in Antibody‐Dependent Enhancement of Dengue Virus Infection in Humans , 2013, Traffic.

[3]  I. Henderson,et al.  Size and Conformation Limits to Secretion of Disulfide-bonded Loops in Autotransporter Proteins* , 2011, The Journal of Biological Chemistry.

[4]  R. Stockley,et al.  Immunity and bacterial colonisation in bronchiectasis , 2011, Thorax.

[5]  D. Maskell,et al.  SadA, a Trimeric Autotransporter from Salmonella enterica Serovar Typhimurium, Can Promote Biofilm Formation and Provides Limited Protection against Infection , 2011, Infection and Immunity.

[6]  Suresh Mahalingam,et al.  Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes , 2010, The Lancet Infectious Diseases.

[7]  D. Bilton,et al.  British Thoracic Society guideline for non-CFbronchiectasis , 2010, Thorax.

[8]  D Bilton,et al.  British Thoracic Society guideline for non-CF bronchiectasis , 2010, Thorax.

[9]  G. Dougan,et al.  Dysregulated Humoral Immunity to Nontyphoidal Salmonella in HIV-Infected African Adults , 2010, Science.

[10]  L. Cavacini,et al.  Structure and function of immunoglobulins. , 2010, The Journal of allergy and clinical immunology.

[11]  M. Molyneux,et al.  Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans , 2010, Proceedings of the National Academy of Sciences.

[12]  D. Bilton.  Update on non-cystic fibrosis bronchiectasis , 2008, Current opinion in pulmonary medicine.

[13]  S. Beatson,et al.  EhaA is a novel autotransporter protein of enterohemorrhagic Escherichia coli O157:H7 that contributes to adhesion and biofilm formation. , 2008, Environmental microbiology.

[14]  G. Pier,et al.  Vaccines and immunotherapy against Pseudomonas aeruginosa. , 2008, Vaccine.

[15]  J. Soriano,et al.  Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. , 2007, Chest.

[16]  M. Martínez-García,et al.  Quality-of-life determinants in patients with clinically stable bronchiectasis. , 2005, Chest.

[17]  M. Frank,et al.  Complement resistance in microbes , 2005, Springer Seminars in Immunopathology.

[18]  Keith A. Joiner,et al.  The role of complement in host resistance to bacteria , 2005, Springer Seminars in Immunopathology.

[19]  I. Henderson,et al.  PicU, a second serine protease autotransporter of uropathogenic Escherichia coli. , 2004, FEMS microbiology letters.

[20]  A. Casadevall,et al.  More Is Not Necessarily Better: Prozone-Like Effects in Passive Immunization with IgG1 , 2003, The Journal of Immunology.

[21]  D. Hodgson,et al.  Light‐induced carotenogenesis in Myxococcus xanthus: functional characterization of the ECF sigma factor CarQ and antisigma factor CarR , 2003, Molecular microbiology.

[22]  M. Keogan,et al.  An investigation into causative factors in patients with bronchiectasis. , 2000, American journal of respiratory and critical care medicine.

[23]  R. Stockley,et al.  IgG subclasses in the serum and sputum from patients with bronchiectasis , 1998, Thorax.

[24]  P. Jones,et al.  Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. , 1997, The European respiratory journal.

[25]  S. Cryz,et al.  Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. , 1997, Behring Institute Mitteilungen.

[26]  A. Fomsgaard,et al.  Specific IgG2 antibodies toPseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis , 1993, Infection.

[27]  T. Bentley,et al.  Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of the 2nd IUIS/WHO collaborative study. , 1992, Immunology letters.

[28]  D. Hornick,et al.  The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion. , 1990, The Journal of clinical investigation.

[29]  A. Cross,et al.  Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans. , 1989, Antibiotics and chemotherapy.

[30]  M. Neuberger,et al.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.

[31]  Normansell De.  Human immunoglobulin subclasses. , 1987 .

[32]  D. Normansell.  Human immunoglobulin subclasses. , 1987, Diagnostic and clinical immunology.

[33]  H. Reynolds,et al.  Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide. , 1986, The American review of respiratory disease.

[34]  T. Bentley,et al.  Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. , 1992, Immunology letters.

[35]  J. Hiller,et al.  Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results. , 1984, Archives of disease in childhood.

[36]  F. Seiler,et al.  [Structure and function of immunoglobulins]. , 1982, Beitrage zu Infusionstherapie und klinische Ernahrung.

[37]  S. Weitzman,et al.  Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. , 1980, The New England journal of medicine.

[38]  SB Halstead,et al.  Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody , 1977, The Journal of experimental medicine.

[39]  D. Holsclaw,et al.  Interactions of Pseudomonas aeruginosa with immunoglobulins and complement in sputum , 1976, Infection and immunity.

[40]  J. Pennington,et al.  Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis. , 1975, The American journal of medicine.

[41]  B. Waisbren,et al.  Bacterial blocking activity of specific IgG in chronic Pseudomonas aeruginosa infection. , 1975, Clinical and experimental immunology.

[42]  B. Waisbren,et al.  A factor in the serum of patients with persisting infection that inhibits the bactericidal activity of normal serum against the organism that is causing the infection. , 1966, Journal of immunology.